Eli Lilly's Once-Weekly Insulin Onswik and Other Key New Drugs Receive Positive CHMP Recommendations

The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for six new drugs, including Eli Lilly's once-weekly basal insulin, Onswik (insulin glargine), and other innovative therapies. This recommendation marks a strategic milestone for Lilly, aiming to capture a leading position in the once-weekly insulin market by significantly improving the convenience of diabetes management. Onswik has demonstrated non-inferior HbA1c reduction compared to existing once-daily formulations in the QWINT Phase 3 trial, paving the way for its market entry. Additionally, Seqirus' influenza vaccine, Aujemflu, and Zambon's Parkinson's disease treatment, Hopledo, have also received positive recommendations, promising to address unmet medical needs in Europe.

Biosimilar Approvals to Reduce Costs and Improve Patient Access in Europe

The CHMP meeting also saw positive recommendations for biosimilars of Amgen's osteoporosis and bone metastasis treatment, Xgeva (denosumab), namely Denosumab Ascend (developed by Ascend Pharma), and Neulasta (pegfilgrastim), namely Nylaspeg (developed by Celltrion Pharma). With the expiration of patents for originator drugs, the availability of more affordable alternatives is expected to significantly reduce the financial burden on European healthcare systems. In particular, the rapid replacement of essential supportive care agents in oncology with biosimilars is likely to dramatically improve patient access to treatment. This increased competition in the biosimilar market also presents a challenge for innovative pharmaceutical companies, requiring them to defend their drug pricing.

Negative Opinions Issued for New Drug Candidates Due to Insufficient Clinical Data and Efficacy

Conversely, the CHMP issued negative opinions for three drugs: Tacquell, a TIL cell therapy for melanoma from the Netherlands Cancer Institute; Yartemlea (narsoplimab) from Omeros for transplant-associated thrombotic microangiopathy; and Xervyteg from MaaT Pharma for acute graft-versus-host disease. These therapies failed to meet the regulatory requirements due to deficiencies in manufacturing process standardization, lack of statistical significance, and insufficient efficacy data. This highlights the importance of meeting the rigorous scientific data requirements of regulatory agencies, as even innovative technologies may be denied market access if these requirements are not met. MaaT Pharma and Omeros, which received the negative opinions, have announced their intention to request a re-examination.

Tavneos Marketing Authorization Recommendation for Revocation Due to Clinical Trial Integrity Concerns

The most significant news is the recommendation to revoke the marketing authorization for Tavneos (avacopan), a treatment for active ANCA-associated vasculitis. The CHMP investigated serious Good Clinical Practice (GCP) violations and data handling errors that occurred during the Phase 3 (ADVOCATE) trial and concluded that the benefits of the drug do not outweigh the risks. This serves as a strong warning that even after drug approval, the integrity of clinical data must be maintained, or the drug may be withdrawn from the market. CSL Vifor, which markets Tavneos in Europe, and Amgen, the original developer, will inevitably suffer a decline in sales, and patients will face a significant gap in treatment options, as there will be no alternative to existing immunosuppressive therapies.